BioCentury | Feb 11, 2020
Finance

Coronavirus could stall China IPOs

...least two other life sciences companies have completed their IPOs so far this year: Suzhou Zelgen...
BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

...$10 Ph II CNS Pharmaceuticals Inc. 6/28/19 $9.6 Preclin Scopus Biopharma Inc. 6/18/19 $4.6 Preclin Suzhou Zelgen Biopharmaceuticals Co. Ltd....
BioCentury | Aug 12, 2019
Finance

Chipscreen sets high standard in Shanghai debut

...a short list of mainland Chinese companies with active applications for STAR, including HitGen Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd....
BioCentury | Jul 31, 2019
Financial News

Chipscreen sets pace for biotech IPOs in Shanghai

...Co. Ltd (Changsha, China). The STAR market’s IPO queue also includes HitGen Inc. (Chengdu, China), Suzhou Zelgen Biopharmaceuticals Co. Ltd....
BioCentury | Jan 19, 2018
Financial News

China's Kintor, Zelgen complete financings

...Suzhou Kintor Pharmaceuticals Inc. (Suzhou, China) and Suzhou Zelgen Biopharmaceuticals Co. Ltd. (Kunshan, China) each completed financings, raising more than...
...receptor antagonist that is in a Phase I/II trial to treat metastatic castration-resistant prostate cancer. Zelgen...
...cancers. Suzhou Zelgen Biopharmaceuticals Co. Ltd., Kunshan, China Suzhou Kintor Pharmaceuticals Inc., Suzhou, China Elizabeth S. Eaton Donafenib Proxalutamide Suzhou Kintor Pharmaceuticals Inc. Suzhou Zelgen...
BioCentury | Jan 16, 2018
Financial News

China's Kintor, Zelgen complete financings

...Suzhou Kintor Pharmaceuticals Inc. (Suzhou, China) and Suzhou Zelgen Biopharmaceuticals Co. Ltd. (Suzhou, China) each completed financings, raising more than...
...receptor antagonist which is in a Phase I/II trial to treat metastatic castration-resistant prostate cancer. Zelgen...
...a multi-target kinase inhibitor in testing to treat various cancers. Elizabeth S. Eaton GT0918 Proxalutamide Suzhou Kintor Pharmaceuticals Inc. Suzhou Zelgen...
Items per page:
1 - 6 of 6
BioCentury | Feb 11, 2020
Finance

Coronavirus could stall China IPOs

...least two other life sciences companies have completed their IPOs so far this year: Suzhou Zelgen...
BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

...$10 Ph II CNS Pharmaceuticals Inc. 6/28/19 $9.6 Preclin Scopus Biopharma Inc. 6/18/19 $4.6 Preclin Suzhou Zelgen Biopharmaceuticals Co. Ltd....
BioCentury | Aug 12, 2019
Finance

Chipscreen sets high standard in Shanghai debut

...a short list of mainland Chinese companies with active applications for STAR, including HitGen Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd....
BioCentury | Jul 31, 2019
Financial News

Chipscreen sets pace for biotech IPOs in Shanghai

...Co. Ltd (Changsha, China). The STAR market’s IPO queue also includes HitGen Inc. (Chengdu, China), Suzhou Zelgen Biopharmaceuticals Co. Ltd....
BioCentury | Jan 19, 2018
Financial News

China's Kintor, Zelgen complete financings

...Suzhou Kintor Pharmaceuticals Inc. (Suzhou, China) and Suzhou Zelgen Biopharmaceuticals Co. Ltd. (Kunshan, China) each completed financings, raising more than...
...receptor antagonist that is in a Phase I/II trial to treat metastatic castration-resistant prostate cancer. Zelgen...
...cancers. Suzhou Zelgen Biopharmaceuticals Co. Ltd., Kunshan, China Suzhou Kintor Pharmaceuticals Inc., Suzhou, China Elizabeth S. Eaton Donafenib Proxalutamide Suzhou Kintor Pharmaceuticals Inc. Suzhou Zelgen...
BioCentury | Jan 16, 2018
Financial News

China's Kintor, Zelgen complete financings

...Suzhou Kintor Pharmaceuticals Inc. (Suzhou, China) and Suzhou Zelgen Biopharmaceuticals Co. Ltd. (Suzhou, China) each completed financings, raising more than...
...receptor antagonist which is in a Phase I/II trial to treat metastatic castration-resistant prostate cancer. Zelgen...
...a multi-target kinase inhibitor in testing to treat various cancers. Elizabeth S. Eaton GT0918 Proxalutamide Suzhou Kintor Pharmaceuticals Inc. Suzhou Zelgen...
Items per page:
1 - 6 of 6